Advanced Cell Technology Announces Exclusive License of Key Intellectual Property Portfolio on Somatic Cell Reprogramming Technology.ALAMEDA, Calif -- Advanced Cell Technology, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ACTC ACTC Apple Certified Technical Coordinator ACTC Almaden Cycle Touring Club ACTC Associated Colleges of the Twin Cities ACTC All Ceylon Tamil Congress (Sri Lanka) ACTC Association Canadienne de Télévision par Câble ) announced today that it has exclusively licensed a key intellectual property portfolio in regard to somatic cell somatic cell n. Any cell of a plant or an animal other than a germ cell. reprogramming Reprogramming refers to erasure and remodeling of epigenetic marks, such as DNA methylation, during mammalian development[1]. After fertilization some cells of the newly formed embryo migrate to the germinal ridge and will eventually become the germ cells from TranXenoGen, Inc., Shrewsbury, Massachusetts Shrewsbury is a town in Worcester County, Massachusetts, United States. Shrewsbury is an unusual New England town in that it was neither a mill town nor a farming village. Rather, it grew as a suburb to neighboring Worcester, Massachusetts from the start. . Advanced Cell Technology believes that the filing date and scope of the intellectual property on this important reprogramming technology could prove to be strategically significant in defining the somatic cell reprogramming patent landscape. The inventions described in the intellectual property portfolio, which are covered by issued and pending patents, cover techniques for the reprogramming of somatic cell nuclei, including the use of extracts for the reprogramming of somatic cell nuclei, for the generation of cloned and/or transgenic animals and for the reprogramming of human cells. We believe that the filing date of February 3rd, 1993 is the earliest patent filing covering somatic cell nuclear transfer Noun 1. somatic cell nuclear transfer - moving a cell nucleus and its genetic material from one cell to another nuclear transplantation, SCNT, somatic cell nuclear transplantation biological research - scientific research conducted by biologists technology. Mr. William Caldwell, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Advanced Cell Technology said, "We are pleased to announce the exclusive licensing of this important intellectual property in the field of cellular reprogramming. After reaching terms with TranXenoGen for an option on this portfolio last year, our team did considerable diligence on this intellectual property portfolio. This portfolio may have the earliest priority date in somatic cell nuclear transfer and is broad in scope of application." About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California Alameda is a city in Alameda County, California, United States. It is located on a small island of the same name next to Oakland, California in the San Francisco Bay. An additional part of the city is Bay Farm Island, which is adjacent to the Oakland International Airport. and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2005. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion